secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001739104-25-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q3 revenue $1.14B (+10% YoY); raises FY guidance, net leverage improves
------------------------------------------------------------------------------

- Q3 revenue $1,137M (+10% reported, +9% organic CC); adjusted EPS $0.19 vs $0.13 YoY (+46%).
- Adjusted EBITDA $198M (+21%); net leverage ratio improved to 3.7x from 4.3x at FY 2024 end.
- Raises FY 2025 revenue guidance to $4,645-4,670M and adjusted EPS to $0.91-0.94 (from $0.85-0.91).
- Pet Health revenue $533M (+10%), driven by Credelio Quattro ($100M net sales in <8 months) and Zenrelia.
- Refinanced $2.1B Term Loan B, extending maturities through 2032 and reducing interest cost.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000068/0001739104-25-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000068/elan-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001739104-25-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer